175 related articles for article (PubMed ID: 12164795)
21. Optimum albumin concentration of supplementation fluid for double filtration plasmapheresis.
Mineshima M; Agishi T; Hasuo Y; Era K; Suzuki T; Teraoka S; Ota K
Artif Organs; 1992 Oct; 16(5):510-3. PubMed ID: 10078302
[TBL] [Abstract][Full Text] [Related]
22. Continuous monitoring of blood volume in double filtration plasmapheresis.
Mineshima M; Eguchi K; Horibe K; Yokoi R; Kaneko I; Kimata N; Sanaka T; Nihei H; Agishi T
ASAIO J; 1998; 44(5):M465-9. PubMed ID: 9804474
[TBL] [Abstract][Full Text] [Related]
23. Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids.
Schmöcker C; Kassner U; Ostermann AI; Kiesler S; Steinhagen-Thiessen E; Schebb NH; Weylandt KH
Atheroscler Suppl; 2017 Nov; 30():193-199. PubMed ID: 29096838
[TBL] [Abstract][Full Text] [Related]
24. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients.
Bramlage CP; Armstrong VW; Zapf A; Bramlage P; Mueller GA; Koziolek MJ
Ther Apher Dial; 2010 Apr; 14(2):136-42. PubMed ID: 20438534
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Fractionation Membranes in an Animal Model of Double Filtration Lipoprotein Apheresis.
Krieter DH; Lange F; Lemke HD; Bonn F; Wanner C
Ther Apher Dial; 2018 Apr; 22(2):189-195. PubMed ID: 29316258
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of lipoprotein apheresis in the management of familial hypercholesterolaemia: Application of two different apheresis techniques in childhood.
Gokay S; Kendirci M; Kaynar L; Solmaz M; Cetin A; Kardas F; Soylu Ustkoyuncu P
Transfus Apher Sci; 2016 Apr; 54(2):282-8. PubMed ID: 26577019
[TBL] [Abstract][Full Text] [Related]
27. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
Tojo K; Sakai S; Miyahara T
Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1153-60. PubMed ID: 3216557
[No Abstract] [Full Text] [Related]
28. Double filtration plasmapheresis in different diseases in Thailand.
Lumlertgul D; Suteeka Y; Tumpong S; Bunnachak D; Boonkaew S
Ther Apher Dial; 2013 Feb; 17(1):99-116. PubMed ID: 23379501
[TBL] [Abstract][Full Text] [Related]
29. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
30. Current topics in therapeutic plasmapheresis.
Nakanishi T; Suzuki N; Kuragano T; Nagasawa Y; Hasuike Y
Clin Exp Nephrol; 2014 Feb; 18(1):41-9. PubMed ID: 23887747
[TBL] [Abstract][Full Text] [Related]
31. Membrane apheresis technology: historical perspective and new trends toward bioincompatible systems.
Nosé Y; Yamaji K; Sueoka A; Yamane S
Ther Apher; 1997 Feb; 1(1):5-12. PubMed ID: 10225773
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
Tojo K; Sakai S; Miyahara T
Prog Clin Biol Res; 1990; 337():193-4. PubMed ID: 2191313
[No Abstract] [Full Text] [Related]
33. The impact of therapeutic plasma exchange and double filtration plasmapheresis on hemostasis in renal transplant recipients.
Vatazin AV; Zulkarnaev AB
Ter Arkh; 2018 Jun; 90(6):22-27. PubMed ID: 30701900
[TBL] [Abstract][Full Text] [Related]
34. Assessment of currently available low-density lipoprotein apheresis systems.
Matsuda Y; Malchesky PS; Nosé Y
Artif Organs; 1994 Jan; 18(1):93-9. PubMed ID: 8141663
[TBL] [Abstract][Full Text] [Related]
35. Analysis of protein removal properties during cryofiltration apheresis using the Evaflux-5A plasma fractionator in a patient with hepatitis C virus-associated cryoglobulinemic glomerulonephritis.
Nakajima H; Kaneko S; Takano T; Hoshino T; Sato Y; Kawase T; Tsukamoto Y
Ther Apher Dial; 2014 Jun; 18(3):258-64. PubMed ID: 24965292
[TBL] [Abstract][Full Text] [Related]
36. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
Julius U; Metzler W; Pietzsch J; Fassbender T; Klingel R
Int J Artif Organs; 2002 Dec; 25(12):1180-8. PubMed ID: 12518963
[TBL] [Abstract][Full Text] [Related]
37. Design of a plasma separator using ceramic membranes.
Sakurai H; Ozawa K; Takesawa S; Sakai K
ASAIO Trans; 1986; 32(1):410-3. PubMed ID: 3778744
[No Abstract] [Full Text] [Related]
38. In vitro characterization of two types of LDL apheresis module and effect of repetitive LDL apheresis on plasma cholesterol levels and aortic atherosclerosis in heterozygous WHHL rabbits.
Kim SS; Kutsumi Y; Nakai T; Miyabo S
Jpn Circ J; 1991 Jan; 55(1):68-80. PubMed ID: 2010950
[TBL] [Abstract][Full Text] [Related]
39. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration).
Geiss HC; Parhofer KG; Donner MG; Schwandt P
Ther Apher; 1999 Aug; 3(3):199-202. PubMed ID: 10427615
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hyperlipidemia with a modified low density lipoprotein apheresis system with dextran sulfate.
Zhao YH; Zou YG; Sun QJ; Xi D; Xing CY
Ther Apher Dial; 2007 Aug; 11(4):249-54. PubMed ID: 17661829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
